Quest Adds New Blood Biomarker to Alzheimer’s Testing Portfolio
Quest Diagnostics expanded its AD-Detect portfolio of Alzheimer’s tests by adding a blood biomarker test for early disease diagnosis.
Quest Diagnostics expanded its AD-Detect portfolio of Alzheimer’s tests by adding a blood biomarker test for early disease diagnosis.
An international research collaboration developed a blood test for the early detection of Alzheimer's disease and mild cognitive impairment.
BrainSee harnesses Darmiyan's patented core proprietary technology, powered by advanced whole-brain image analysis and medical AI.
Resonant published research revealing a blood biomarker of neurodegeneration that achieved 100% accuracy in identifying Alzheimer’s patients.
Read MoreThe biomarkers included in the company’s Precivity blood tests help healthcare providers determine amyloid plaques presence in the brain.
Read MoreDiadem formed a strategic collaboration with Quest Diagnostics to improve access to blood tests for evaluating the risk of Alzheimer’s.
Read MoreIndiana University School of Medicine researchers will play key roles in a consortium studying biomarkers for Alzheimer’s diagnosis.
Read MoreLucent Diagnostics, a diagnostics brand of Quanterix Corp., launched a high-accuracy p-Tau 217 blood test for Alzheimer’s disease.
Read MorePharmaKure announced successful study results for a novel whole-blood test for quantifying Alzheimer’s Disease biomarkers.
Read MoreLabcorp’s blood-based test combines three blood biomarkers to identify and assess biological changes associated with Alzheimer’s disease.
Read MoreResearchers confirmed the usefulness of NfL blood levels to predict the likelihood of progression of neurodegeneration in Alzheimer’s.
Read MoreA new blood test shows promise as an Alzheimer’s biomarker, and when used in a two-step workflow high accuracy to find brain amyloidosis.
Read MoreResearchers identified a way with a fitness tracker to assess brain activity in sleep that occurs in the earliest stages of Alzheimer’s.
Read MoreMedical director Zaldy Tan, MD, MPH, answers questions about the Alzheimer’s blood test, as well as similar tests that are in development.
Read MoreC2N Diagnostics, has released the PrecivityAD2 blood test, that meets the standard of care with PET scans and cerebrospinal fluid tests.
Read MoreC2N Diagnostics says new research affirms the clinical utility of its PrecivityAD blood test to help diagnose Alzheimer’s.
Read MoreQuest announced the availability a blood test for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease.
Read MoreLow spinal fluid levels of a protein linked to learning and memory in mice may serve as an early predictor of mild cognitive impairment.
Read More